Pyrazinoic Acid

Pyrazinoic Acid

SCHEMBL970038

O=C([O-])c1cnccn1.O=C([O-])c1cnccn1.[Cu+2]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.61
NAPRT Q6XQN6 1/20 0.61
HCAR2 Q8TDS4 1/20 0.61
ADORA3 P0DMS8 1/20 0.59
TSHR P16473 1/20 0.59
MC4R P32245 1/20 0.59
ADRA1A P35348 1/20 0.59
MC3R P41968 1/20 0.59
BAZ2B Q9UIF8 1/20 0.48
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MCL1 Q07820 1/20 0.42
PABPC1 P11940 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrazinoic Acid SCHEMBL2158528 1.00 KDM4E (0.61) KDM4ENAPRTHCAR2ADORA3TSHR
Pyrazinoic Acid SCHEMBL11128823 0.95 KDM4E (0.61) KDM4ENAPRTHCAR2ADORA3TSHR
Pyrazinoic Acid SCHEMBL28360997 0.95 KDM4E (0.61) KDM4ENAPRTHCAR2ADORA3TSHR
Pyrazinoic Acid SCHEMBL8626539 0.95 KDM4E (0.61) KDM4ENAPRTHCAR2ADORA3TSHR
SCHEMBL7618500 0.78 KDM4E (0.70) KDM4ENAPRTHCAR2ADORA3TSHR
SCHEMBL3186159 0.78 KDM4E (0.70) KDM4ENAPRTHCAR2ADORA3TSHR
Pyrazinamide SCHEMBL30205948 0.77 ADORA3 (0.84) KDM4ENAPRTHCAR2ADORA3TSHR
Pyrazinamide SCHEMBL28919855 0.77 ADORA3 (0.84) KDM4ENAPRTHCAR2ADORA3TSHR
Pyrazinamide SCHEMBL28169840 0.77 ADORA3 (0.84) KDM4ENAPRTHCAR2ADORA3TSHR
SCHEMBL2536804 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747238-A1 PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS Sanofi (FR) 2026-05-27 EP claimed
WO-2025021696-A1 PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS SANOFI (FR) 2025-01-30 WO claimed
EP-4187558-B1 APPLICATION OF AN ADDITIVE IN A PREPARATION METHOD OF A SAMARIUM-COBALT 2:17 TYPE MAGNET FUJIAN CHANGTING ZORR TECH CO LTD (CN) 2024-07-24 EP claimed
EP-4187558-A1 ADDITIVE AND APPLICATION THEREOF, AND SAMARIUM-COBALT 2: 17 TYPE MAGNET AND PREPARATION METHOD THEREOF Fujian Changting Zorr Technology Co., Ltd. (CN) 2023-05-31 EP claimed
CN-114255945-A Additive and application thereof, 2-17 type samarium-cobalt magnet and preparation method thereof 福建省长汀卓尔科技股份有限公司 2022-03-29 CN claimed
US-9346686-B2 Copper-containing nanocrystals and methods of preparation therefor THE UNIVERSITY OF WESTERN ONTARIO (CA) 2016-05-24 US claimed
US-20150360967-A1 COPPER-CONTAINING NANOCRYSTALS AND METHODS OF PREPARATION THEREFOR THE UNIVERSITY OF WESTERN ONTARIO (CA) 2015-12-17 US claimed
US-7867676-B2 Copper containing hole blocking layer photoconductors XEROX CORPORATION (US) 2011-01-11 US claimed
US-20090035675-A1 COPPER CONTAINING HOLE BLOCKING LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-02-05 US claimed
EP-1121335-B1 IMPROVED GAS GENERATING COMPOSITION ATLANTIC RES CORP (US) 2005-09-21 EP claimed
EP-1121335-A4 IMPROVED GAS GENERATING COMPOSITION ATLANTIC RES CORP (US) 2002-10-16 EP claimed
EP-1121335-A2 IMPROVED GAS GENERATING COMPOSITION ATLANTIC RESEARCH CORPORATION (US) 2001-08-08 EP claimed
US-6136113-A A EUTECTIC MIXTURE OR SOLID SOLUTION-FORMING MIXTURE OF AMMONIUM NITRATE, GUANIDINE NITRATE AND/OR AMINOGUANIDINE NITRATE, POTASSIUM OR CESIUM NITRATE OR PERCHLORATE, A POLYVINYL ALCOHOL BINDER, COPPER OR COPPER COMPOUND CATALYST ATLANTIC RESEARCH CORPORATION (US) 2000-10-24 US claimed
WO-2000007846-A2 IMPROVED GAS GENERATING COMPOSITION ATLANTIC RESEARCH CORPORATION (US) 2000-02-17 WO claimed
EP-4747238-A1 PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS Sanofi (FR) 2026-05-27 EP disclosed
US-12577413-B2 Anti-microbial surfaces and related methods HENKEL AG & CO. KGAA (DE) 2026-03-17 US disclosed
US-20250376428-A1 DIARYL ETHER COMPOUND AND MANUFACTURING METHOD FROM LIGNIN ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) 2025-12-11 US disclosed
EP-1704057-A1 LASER IMAGING Sherwood Technology LTD. (GB) 2006-09-27 EP disclosed
EP-1121335-B1 IMPROVED GAS GENERATING COMPOSITION ATLANTIC RES CORP (US) 2005-09-21 EP disclosed
WO-2005068207-A1 LASER IMAGING DATALASE LTD. (GB) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376428-A1 DIARYL ETHER COMPOUND AND MANUFACTURING METHOD FROM LIGNIN DCXR, LSS, LCT KDM4E 47/4885NAPRT 599/4885HCAR2 3420/4885
US-12577413-B2 Anti-microbial surfaces and related methods SMC3, MSR1, SPOUT1 KDM4E 1270/4885NAPRT 4597/4885HCAR2 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.